Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

433P - Clinical characterization of tracheal and pulmonary adenoid cystic carcinoma: A French institutional experience

Date

28 Mar 2025

Session

Poster Display session

Presenters

Èlia Sais

Citation

Journal of Thoracic Oncology (2025) 20 (3): S241-S255. 10.1016/S1556-0864(25)00632-X

Authors

È. Sais1, D. Diaz-Jimenez2, D. Miliziano2, L. Zullo2, M.R. Ghigna3, A. Lopez-Gutierrez2, V. Thomas de Montpreville4, O. Mercier5, P. Lavaud6, D. Planchard2, F. Barlesi3, C. Le Pechoux2, A. Levy2, A. Botticella3, B. Besse2, J. REMON MASIP2

Author affiliations

  • 1 ICO Girona - Institut Català d'Oncologia Girona, Girona/ES
  • 2 Institut Gustave Roussy, Villejuif/FR
  • 3 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 4 Hospital Marie Lannelongue, Le Plessis-Robinson/FR
  • 5 Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson/FR
  • 6 Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 433P

Background

Lung adenoid cystic carcinoma (LACC) and tracheal adenoid cystic carcinoma (TACC) are considered rare thoracic malignancies with low incidence rates. LACC is more aggressive due to its higher metastatic potential compared to TACC. However, due to the rarity of these tumors, limited data exists on their clinicopathological and molecular characteristics. The current study cohort aimed to examine the clinicopathologic features and outcomes of these malignancies in a single-center study.

Methods

We retrospectively analyzed all histologically confirmed cases of LACC and TACC diagnosed at Gustave Roussy. Clinical, pathological, and molecular data were collected via REDCap database and vital status was reviewed as of December 31, 2024. Descriptive analyses, progression free survival (PFS) and overall survival (OS)were evaluated. Survival outcomes were and analyzed using the Kaplan-Meier method and compared via the log-rank test.

Results

From June 1989 to October 2024 34 patients were enrolled, n=18 (52.9%) with LACC and n=16 (47.1%) with TACC. The median age was 46 years (range 18–82),19 (56%) patients being female. At baseline, all TACC cases presented with localized disease, while n=2 (11%) of LACC cases were metastatic (pleural and lung metastases). Overall, 94% of patients underwent local treatment. After a median follow-up of 5.7 years, n=19 (56%) of patients experienced disease progression. The most common metastatic sites were the lung (24.5%) followed by bone (10.2%), liver (10.2%), brain (6,1%), lymph nodes (6,1%), pleural (4,1%), meningeal (2%) and renal (2%). The median progression-free survival (PFS) for the LACC was 88.7 months (95% CI: 20.29–157.23) and 120 months (95% CI: 13.271–226.742) for TACC (long rank test: x2=2.455, df=1, p=0.117). Median overall survival (mOS) for LACC was 140.7 months (95% CI: 46.082–231.023), while TACC OS was not reached. For two patients with metastatic LACC, median PFS was 30.35 months (immature data for OS).

Conclusions

LACC and TACC are rare thoracic malignancies typically diagnosed in young patients. Despite the aggressiveness of LACC, localized cases demonstrate a survival exceeding 10 years, emphasizing the importance of early detection and surgical intervention.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.